PDUFA Date Explained: Complete Guide to FDA Action Dates and the 2026 Approval Calendar

A PDUFA date is the target date by which the FDA commits to completing its review of a New Drug Application (NDA) or Biologics License Application (BLA) under the Prescription Drug User Fee Act. This date - also called the FDA goal date, action date, or target action date - represents a performance commitment rather than a legal deadline, though FDA consistently meets over 90% of PDUFA date goals.

For pharmaceutical and biotech companies, investors, and regulatory professionals, PDUFA dates represent critical milestones that can significantly impact stock prices, launch timelines, and strategic planning. Missing a PDUFA date or receiving a Complete Response Letter (CRL) instead of an approval can delay market entry by months or years.

In this guide, you will learn:

• What a PDUFA date means and how FDA calculates these target action dates
• The difference between standard review (10 months) and priority review (6 months) PDUFA timelines
• Current PDUFA VII commitments and FDA performance goals for FY 2023-2027
• How to track upcoming PDUFA dates on the 2026 FDA approval calendar
• What happens when FDA misses a PDUFA date or issues a Complete Response Letter

What Is a PDUFA Date? Understanding FDA Goal Dates

A PDUFA date is the deadline FDA sets for completing its review of a drug or biologic application. The term derives from the Prescription Drug User Fee Act (PDUFA), first enacted in 1992, which established a system where pharmaceutical companies pay user fees to fund FDA review staff in exchange for FDA committing to specific review timeframes.

Key characteristics of PDUFA dates:

• Represents a goal date, not a legally binding deadline
• Calculated from the date FDA accepts the application for filing (not submission date)
• Varies based on review type: standard review (10 months) or priority review (6 months)
• Applies to original NDA and BLA submissions, not supplements or amendments
• Can be extended by three months if FDA requests additional information (Major Amendment)

The PDUFA date system has transformed FDA drug review. Before PDUFA, median review times exceeded 30 months. Under current PDUFA VII commitments, median approval times have dropped to approximately 10-12 months for standard reviews and 6-8 months for priority reviews.

How FDA Action Dates Are Calculated: Filing to Goal Date

Understanding how FDA action dates are calculated helps sponsors and stakeholders accurately predict decision timelines. The PDUFA date calculation involves several distinct phases.

Phase 1: Day 0 - Application Submission

The process begins when a sponsor submits an NDA or BLA to FDA through the Electronic Submissions Gateway (ESG). This submission date is considered "Day 0" but is not when the PDUFA clock starts.

Phase 2: Filing Review (Days 1-60)

After receiving the application, FDA has 60 calendar days to determine whether the submission is complete enough for substantive review. This is called the "filing review" or "refuse to file" (RTF) period.

Possible outcomes of filing review:

• File decision: FDA accepts the application for review; PDUFA clock starts
• Refuse to File (RTF): FDA determines the application is incomplete; sponsor must resubmit
• Filing issues identified: FDA may request clarification but proceed with filing

“

Important: The PDUFA date is calculated from the filing date (Day 60 determination), not the original submission date. If FDA files the application on Day 60, that becomes the official "filing date" from which the review clock runs.

Phase 3: PDUFA Clock Calculation

Once FDA files the application, the PDUFA goal date is calculated based on review type:

Example PDUFA Date Calculation

Standard Review vs Priority Review: PDUFA Timeline Comparison

The PDUFA calendar distinguishes between two primary review types, each with different timelines and eligibility criteria.

Standard Review (10-Month Timeline)

Standard review applies to all original NDA and BLA applications that do not qualify for priority review. Under PDUFA VII, FDA commits to reviewing 90% of standard applications within 10 months of the filing date.

Standard review characteristics:

• 10-month review timeline from filing date
• Applies to drugs offering similar therapeutic benefit to existing treatments
• Includes one formal mid-cycle communication opportunity
• User fee: $4,682,003 for FY 2026 (application requiring clinical data)

Priority Review (6-Month Timeline)

Priority review is granted to drugs that would provide significant improvements in the treatment, diagnosis, or prevention of serious conditions. Under PDUFA VII, FDA commits to reviewing 90% of priority applications within 6 months of the filing date.

Priority review eligibility criteria:

• Significant improvement in safety or effectiveness
• Treatment of serious condition with unmet medical need
• Can be combined with other expedited programs (Fast Track, Breakthrough Therapy)

Priority Review Voucher Program

Certain applications - including those for rare pediatric diseases, tropical diseases, and medical countermeasures - may earn a Priority Review Voucher (PRV) upon approval. This voucher can be redeemed on a future application or sold to another company.

“

Key Statistic: Priority Review Vouchers have sold for $100-350 million, reflecting the significant value of the 4-month reduction in review time.

PDUFA Dates 2026: Major Upcoming FDA Decisions

Tracking PDUFA dates 2026 provides critical intelligence for investors, competitors, and regulatory professionals monitoring the pharmaceutical landscape. While FDA does not publish an official public calendar of all PDUFA dates, several sources compile this information.

Notable 2026 PDUFA Dates by Quarter

The following represents anticipated FDA action dates based on publicly disclosed information. Companies typically disclose PDUFA dates in SEC filings, press releases, and earnings calls.

Q1 2026 (January - March)

Q2 2026 (April - June)

Q3 2026 (July - September)

Q4 2026 (October - December)

“

Note: Specific PDUFA dates are typically disclosed by sponsors through press releases and SEC filings. FDA does not maintain a public calendar of pending applications due to confidentiality requirements.

How to Find Upcoming PDUFA Dates

FDA Approval Calendar: Understanding the Review Process

The FDA approval calendar encompasses the entire review timeline from submission through decision. Understanding this process helps set appropriate expectations for PDUFA dates.

FDA Review Activities During PDUFA Period

Information Requests and PDUFA Extensions

FDA may extend a PDUFA date by three months if the agency issues a Major Amendment request - a request for significant additional information or studies that FDA cannot evaluate within the original timeframe.

Types of FDA information requests:

“

Important: A Major Amendment extends the PDUFA date by 3 months from the date FDA receives the sponsor's response, not from the date FDA issues the request.

PDUFA VII Commitments: Current FDA Performance Goals

PDUFA VII, covering fiscal years 2023-2027, establishes current FDA review commitments. These performance goals represent FDA's commitment to industry in exchange for user fee funding.

PDUFA VII Review Timeline Commitments

PDUFA VII Key Enhancements

PDUFA VII introduced several improvements over previous PDUFA iterations:

1. Enhanced Communication Commitments

• Mid-cycle meetings for all original applications
• Increased pre-submission meeting opportunities
• Improved feedback on clinical trial designs

2. Rare Disease Program Enhancements

• Dedicated rare disease staff
• Flexible approaches for small patient populations
• Enhanced natural history study guidance

3. Complex Innovative Trial Designs

• Support for adaptive trial designs
• Master protocols guidance
• Real-world evidence integration

4. Information Technology Modernization

• Electronic submission enhancements
• Improved submission tracking systems
• Digital health regulatory frameworks

Historical FDA Performance Against PDUFA Goals

“

Key Statistic: FDA has consistently exceeded its 90% on-time target for both standard and priority reviews, typically achieving 92-96% on-time performance.

PDUFA Calendar Management: What Happens When FDA Misses the Date

While FDA meets most PDUFA dates, understanding what happens when the agency misses a goal date is important for planning purposes.

Reasons FDA May Miss a PDUFA Date

FDA Actions When Missing PDUFA Date

When FDA cannot meet a PDUFA date, the agency typically:

1. Notifies the sponsor in advance when possible
2. Provides a new target date or timeline estimate
3. Continues review activities without formal deadline
4. Issues decision when review is complete

“

Important: Missing a PDUFA date does not mean rejection. FDA may simply need additional time to complete its review. Many drugs approved after PDUFA date delays go on to receive approval within weeks or months.

Complete Response Letters (CRLs)

A Complete Response Letter indicates FDA cannot approve the application in its present form. CRLs represent a formal cycle completion, not a final rejection.

Common CRL reasons:

• Clinical efficacy or safety concerns
• Chemistry, Manufacturing, and Controls (CMC) deficiencies
• Labeling disagreements
• GMP inspection failures
• Missing or inadequate data

Tracking PDUFA Dates: Resources and Best Practices

Successfully tracking PDUFA dates requires systematic monitoring of multiple information sources.

Primary PDUFA Date Tracking Resources

Best Practices for PDUFA Date Monitoring

For Pharmaceutical Companies:

1. Maintain internal PDUFA tracking systems
2. Monitor competitor PDUFA dates for market intelligence
3. Plan launch activities around PDUFA date ranges
4. Prepare for multiple scenarios (approval, CRL, extension)

For Investors:

1. Track PDUFA dates for portfolio companies
2. Monitor FDA review history for similar drugs
3. Assess probability of on-time approval
4. Consider PDUFA date volatility in investment timing

For Regulatory Professionals:

1. Calendar all relevant PDUFA dates
2. Track FDA inspection schedules
3. Monitor FDA guidance and communication patterns
4. Prepare responses for potential information requests

Key Takeaways

Next Steps

Understanding PDUFA dates is essential for planning drug development timelines, launch preparations, and competitive intelligence. Whether you are tracking your own submission or monitoring the competitive landscape, accurate PDUFA date intelligence drives better decision-making.

Organizations managing regulatory submissions benefit from automated validation tools that catch errors before gateway rejection. Assyro's AI-powered platform validates eCTD submissions against FDA, EMA, and Health Canada requirements, providing detailed error reports and remediation guidance before submission.

Sources